X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare FDC LTD. with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FDC LTD. vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FDC LTD. DISHMAN PHARMA FDC LTD./
DISHMAN PHARMA
 
P/E (TTM) x 29.1 25.1 115.8% View Chart
P/BV x 6.1 3.3 181.0% View Chart
Dividend Yield % 0.8 0.7 117.6%  

Financials

 FDC LTD.   DISHMAN PHARMA
EQUITY SHARE DATA
    FDC LTD.
Mar-14
DISHMAN PHARMA
Mar-16
FDC LTD./
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs144374 38.3%   
Low Rs79129 61.3%   
Sales per share (Unadj.) Rs47.6197.8 24.0%  
Earnings per share (Unadj.) Rs7.621.2 35.9%  
Cash flow per share (Unadj.) Rs9.034.7 25.9%  
Dividends per share (Unadj.) Rs2.252.00 112.5%  
Dividend yield (eoy) %2.00.8 254.5%  
Book value per share (Unadj.) Rs47.5179.9 26.4%  
Shares outstanding (eoy) m177.8380.69 220.4%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.31.3 183.8%   
Avg P/E ratio x14.611.9 123.2%  
P/CF ratio (eoy) x12.37.2 170.4%  
Price / Book Value ratio x2.31.4 167.3%  
Dividend payout %29.69.4 313.5%   
Avg Mkt Cap Rs m19,78420,306 97.4%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,2215,355 22.8%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m8,45915,961 53.0%  
Other income Rs m394265 148.3%   
Total revenues Rs m8,85216,226 54.6%   
Gross profit Rs m2,0704,103 50.5%  
Depreciation Rs m2491,091 22.8%   
Interest Rs m31944 3.3%   
Profit before tax Rs m2,1842,334 93.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2251 -20,445.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m606624 97.1%   
Profit after tax Rs m1,3531,711 79.1%  
Gross profit margin %24.525.7 95.2%  
Effective tax rate %27.726.7 103.8%   
Net profit margin %16.010.7 149.2%  
BALANCE SHEET DATA
Current assets Rs m4,35511,018 39.5%   
Current liabilities Rs m1,7929,517 18.8%   
Net working cap to sales %30.39.4 322.3%  
Current ratio x2.41.2 209.9%  
Inventory Days Days44110 40.2%  
Debtors Days Days2535 70.8%  
Net fixed assets Rs m3,02516,304 18.6%   
Share capital Rs m179161 110.7%   
"Free" reserves Rs m8,24312,907 63.9%   
Net worth Rs m8,45314,516 58.2%   
Long term debt Rs m114,189 0.3%   
Total assets Rs m10,55729,805 35.4%  
Interest coverage x71.43.5 2,057.5%   
Debt to equity ratio x00.3 0.4%  
Sales to assets ratio x0.80.5 149.6%   
Return on assets %13.18.9 147.2%  
Return on equity %16.011.8 135.8%  
Return on capital %23.517.5 134.1%  
Exports to sales %13.324.8 53.7%   
Imports to sales %3.33.7 89.5%   
Exports (fob) Rs m1,1263,956 28.5%   
Imports (cif) Rs m283596 47.4%   
Fx inflow Rs m1,1464,952 23.1%   
Fx outflow Rs m355697 51.0%   
Net fx Rs m7914,255 18.6%   
CASH FLOW
From Operations Rs m1,4852,786 53.3%  
From Investments Rs m-620-1,529 40.5%  
From Financial Activity Rs m-753-941 80.0%  
Net Cashflow Rs m113316 35.7%  

Share Holding

Indian Promoters % 68.9 61.4 112.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.7 3.7 127.0%  
FIIs % 7.5 12.7 59.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.0 22.1 86.0%  
Shareholders   23,730 46,261 51.3%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FDC LTD. With:   TTK HEALTHCARE  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare FDC LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FDC LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK FDC LTD.

  • Track your investment in FDC LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FDC LTD. - ASTRAZENECA PHARMA COMPARISON

COMPARE FDC LTD. WITH

MARKET STATS